Abstract
Traditional medicine has been a reliable source for the discovery of
molecules with therapeutic activity against human diseases of clinical interest. In the
past, knowledge of traditional medicine was mainly transmitted orally and in writing.
Recently, the advent of “multiomics” tools (transcriptomics, metabolomics,
epigenomics, proteomics, and lipidomics, among others) has increased and merged our
knowledge, both traditional knowledge and that gained with these new multiomics
technologies. In this way, the development of medicines with these 'multiomics
technologies' has allowed pharmaceutical advances in the discovery of new drugs. In
addition, 'multiomics' technologies have made it possible to uncover new biological
activities of drugs that are currently used in clinical therapy. In the same way,
'multiomics' has allowed for the development of 'personalized medicine', that is, a
particular and specific treatment and/or diagnosis of a patient with respect to a disease.
Therefore, 'multiomics' technologies have facilitated the discovery of new clinical
therapeutics for disease, as well as allowing for the diagnosis and/or treatment of
diseases in an individual and personalized way.